RWA Wealth Partners LLC Sells 745 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

RWA Wealth Partners LLC lowered its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,289 shares of the financial services provider’s stock after selling 745 shares during the quarter. RWA Wealth Partners LLC’s holdings in iShares Biotechnology ETF were worth $1,493,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IBB. National Bank of Canada FI increased its holdings in iShares Biotechnology ETF by 5.9% during the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares in the last quarter. IFP Advisors Inc raised its position in iShares Biotechnology ETF by 237.1% in the 4th quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after buying an additional 11,266 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in iShares Biotechnology ETF in the 4th quarter valued at approximately $480,000. Main Management ETF Advisors LLC boosted its position in iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after acquiring an additional 14,535 shares during the last quarter. Finally, Cullen Frost Bankers Inc. grew its stake in shares of iShares Biotechnology ETF by 1.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after acquiring an additional 82 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 1.8 %

NASDAQ IBB opened at $127.90 on Tuesday. The firm’s 50 day moving average is $136.07 and its 200-day moving average is $138.74. The company has a market capitalization of $6.04 billion, a PE ratio of 27.83 and a beta of 0.84. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57.

iShares Biotechnology ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were paid a dividend of $0.1212 per share. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.